Coherus Oncology, Inc. financial data

Symbol
CHRS on Nasdaq
Location
Redwood City, CA
Fiscal year end
31 December
Latest financial report
8-K - Q4 2024 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 127% % 2%
Quick Ratio 1% % -89%
Debt-to-equity -1746% % -159%
Return On Assets 35% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 120,871,013 shares 4.9%
Common Stock, Shares, Outstanding 116,236,018 shares 0.89%
Entity Public Float $170,600,000 USD -47%
Common Stock, Value, Issued $12,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 116,229,170 shares 0.88%
Weighted Average Number of Shares Outstanding, Diluted 116,229,170 shares 0.88%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $98,673,000 USD 17%
Costs and Expenses $217,795,000 USD 142%
Operating Income (Loss) $180,638,000 USD 23%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $181,685,000 USD 22%
Net Income (Loss) Attributable to Parent $154,971,000 USD -230%
Earnings Per Share, Basic 1 USD/shares 3175%
Earnings Per Share, Diluted 1 USD/shares 3175%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $103,352,000 USD 5.8%
Marketable Securities, Current $88,311,000 USD
Inventory, Net $2,048,000 USD -96%
Assets, Current $460,955,000 USD 25%
Property, Plant and Equipment, Net $1,633,000 USD -44%
Operating Lease, Right-of-Use Asset $4,518,000 USD -24%
Other Assets, Noncurrent $4,447,000 USD -40%
Assets $516,519,000 USD 2.3%
Accounts Payable, Current $24,893,000 USD 14%
Employee-related Liabilities, Current $13,385,000 USD -15%
Accrued Liabilities, Current $13,101,000 USD -79%
Liabilities, Current $372,297,000 USD 26%
Deferred Income Tax Liabilities, Net $1,102,000 USD 0%
Operating Lease, Liability, Noncurrent $3,286,000 USD -34%
Other Liabilities, Noncurrent $17,545,000 USD -40%
Liabilities $428,745,000 USD -28%
Accumulated Other Comprehensive Income (Loss), Net of Tax $203,000 USD 26%
Retained Earnings (Accumulated Deficit) $1,345,326,000 USD 10%
Stockholders' Equity Attributable to Parent $87,774,000 USD
Liabilities and Equity $516,519,000 USD 2.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $25,826,000 USD 45%
Net Cash Provided by (Used in) Financing Activities $264,000 USD -130%
Net Cash Provided by (Used in) Investing Activities $17,486,000 USD -109%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 116,236,018 shares 0.89%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $43,576,000 USD -128%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $103,592,000 USD 5.8%
Deferred Tax Assets, Valuation Allowance $412,833,000 USD -2.5%
Deferred Tax Assets, Gross $419,149,000 USD -2.6%
Operating Lease, Liability $4,977,000 USD -22%
Lessee, Operating Lease, Liability, to be Paid $5,848,000 USD -26%
Operating Lease, Liability, Current $1,691,000 USD 19%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,126,000 USD -3%
Lessee, Operating Lease, Liability, to be Paid, Year One $2,192,000 USD 4.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $871,000 USD -44%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,530,000 USD -28%
Deferred Tax Assets, Operating Loss Carryforwards $158,090,000 USD -7.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $19,247,000 USD 11%
Additional Paid in Capital $1,433,291,000 USD 1.5%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets $2,700,000 USD -36%
Depreciation, Depletion and Amortization $1,100,000 USD 38%
Deferred Tax Assets, Net of Valuation Allowance $6,316,000 USD -7.6%
Share-based Payment Arrangement, Expense $20,566,000 USD -36%
Interest Expense $7,479,000 USD -18%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%